Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACNU + vincristine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ACNU + vincristine is a chemotherapy combination used primarily for treating certain types of cancer, particularly anaplastic carcinoma of the lung. This combination therapy was designed to address the heterogeneous nature of anaplastic carcinoma, which can include undifferentiated squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and small cell carcinoma. ACNU (nimustine) is a nitrosourea compound that acts as an alkylating agent, cross-linking DNA and inhibiting cancer cell growth. Vincristine is a vinca alkaloid that binds to tubulin, preventing microtubule formation during cell division, thus stopping cancer cells from dividing.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ACNU + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACNU + vincristine.